CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 73 enrolled
Drug / intervention
Epiduo Gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01522456
NCT01522456Phase 4Completed
CompareCT.gov

Split-face Tolerability Comparison Between Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Versus Retin-A Micro® (Tretinoin Gel) Microsphere, 0.1% in Subjects With Acne Vulgaris

Galderma R&D·interventional·Posted Jan 31, 2012·Updated Aug 1, 2022

In Brief

A Phase 4 clinical trial evaluating Epiduo Gel and Retin-A Micro Microsphere 0.1% for Acne Vulgaris. Completed, enrolled 73 participants across 1 site.

Detailed Summary

To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 31, 2012
Enrollment StartApr 1, 2012
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.4 years ago

Interventions

Epiduo Geldrug

Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.

Retin-A Micro Microsphere 0.1%drug

Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.